Ketorolac Trometamol Kent Pharma Uk (Ketorolac Trometamol)

The drug blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels decrease inflammation and peripheral sensitisation of pain receptors, providing potent analgesic effects.

The specific dose and duration are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and route of administration. Ketorolac is typically limited to a maximum of five days of therapy.

Ketorolac is generally avoided during pregnancy, especially in the third trimester, because of potential fetal renal effects and bleeding risk. Limited data exist for breastfeeding; therefore, use should be considered only if the potential benefit justifies the possible risk to the infant.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Ketorolac is distinguished by its strong analgesic potency, comparable to moderate‑strength opioids, and a rapid onset when given intravenously or intramuscularly. Unlike many NSAIDs, it is typically reserved for short‑term use because of higher risks of renal and gastrointestinal adverse effects.

The product should be stored below 25 °C in its original packaging, protected from moisture and light. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution appears discoloured.

Ketorolac Trometamol is supplied for intramuscular or intravenous injection. The preparation is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional, typically as a single dose or repeated doses under strict time limits.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe allergic reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke, particularly in patients with existing risk factors.

Ketorolac is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, severe renal impairment, recent coronary artery bypass graft surgery, and in those receiving anticoagulant therapy where bleeding risk is unacceptable.